The U.S. Food and Drug Administration awarded a $48,715.20 firm fixed-price purchase order to Pacific Biosciences of California, Inc. for Revio reagent kits (part number 102-817-900) with an ultimate completion date of September 9, 2024. This award represents a direct procurement of consumable supplies critical to next-generation DNA sequencing operations. Pacific Biosciences is a leading biotechnology manufacturer headquartered in Menlo Park, California, specializing in advanced sequencing technologies and associated reagent consumables. The purchase order carries no set-aside designation and is being performed at the vendor's primary facility in Menlo Park, California.
This award likely derives from or is executed under the FDA's existing Indefinite Delivery Indefinite Quantity contract with Pacific Biosciences, valued at $1 million and awarded on March 31, 2021, which extends through March 2025 and provides flexible procurement authority for sequencing reagents, kits, and consumables. The Revio platform represents Pacific Biosciences' advanced long-read sequencing system, and these reagent kits enable the agency's genomic research, regulatory review activities, and food safety initiatives at facilities including the National Center for Toxicological Research and Centers for Food Safety and Applied Nutrition. The reagent consumables procured under this purchase order support the FDA's broader scientific capabilities in genomic analysis supporting regulatory science and product safety assessment.